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Background: The demand for effective strategies for maintaining cognitive capableness
and establishing early dementia diagnosis has been tremendous, especially in
the context of population aging. However, studies on the elderly population and
neurocognitive impairment had provided ambiguous results throughout, while potential
blood biomarkers of cognitive decline are yet to be clearly understood.
Objectives: The present study is aimed at assessing the relationship between blood
lipids—especially in the context of their usefulness as biomarkers of an early cognitive
decline—and cognitive functioning of aging adults.
Materials and Methods: The study sample consisted of 230 participants—(109 women,
121 men) aged 65+ years. Plasma 24(S)-hydroxycholesterol [24(S)-OHC], serum total
cholesterol (TC), high-density lipoprotein cholesterol (HDL), and low-density lipoprotein
cholesterol (LDL) were assessed. The analyses were conducted in three groups
of cognitive performance: cognitively normal, mild cognitive impairment (MCI), and
mild dementia, of which the subjects were divided with the Mini-Mental State
Examination (MMSE).
Abbreviations: 24(S)-OHC, 24(S)-hydroxycholesterol; 27-OHC, 27(S)-hydroxycholesterol; 7α-OHC, 7α-hydroxycholesterol;
7β-OHC, 7β-hydroxycholesterol; AD, Alzheimer’s disease; ADL, Activities of Daily Living; APP, amyloid-precursor protein;
BBB, blood-brain barrier; CSF, cerebrospinal fluid; CYP46A1, 24-hydroxylase; GDS-15, 15 item version of the Geriatric
Depression Scale; HDL, high-density lipoprotein; IADL, Instrumental Activities of Daily Living; LDL, low-density lipoprotein;
MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; TC, total cholesterol; VaD, vascular dementia.
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Results: No significant differences in 24(S)-OHC plasma concentrations for different
levels of cognitive performance were found. Significant differences were found in serum
TC (p = 0.026) and LDL (p = 0.007) concentrations for different levels of cognitive
performance. Concentrations of both parameters were highest in the MCI group and
lowest in mild dementia and cognitive norm, respectively. No significant differences
between serum HDL concentrations and cognitive performance were found.
Conclusions: To fully assess the potential of research on blood lipids in regards to a
cognitive decline, cross-sectional or epidemiological studies aimed at further exploring
blood lipid roles in both the early and advanced MCI and dementia, are needed.
Keywords: neurodegeneration, mild cognitive impairment, dementia, cognition, cholesterol, biomarker,
24(S)-hydroxycholesterol, plasma
HIGHLIGHTS
- No differences in 24(S)-OHC plasma concentrations for
different levels of cognitive performance were observed
- Concentrations of both total cholesterol and LDL fraction were
highest in the MCI group
- 24(S)-OHC cannot be qualified as a blood biomarker of an
early neurodegeneration
INTRODUCTION
Cholesterol is a pivotal constituent of neurons, and the brain
is its most substantial source, sustaining about 25% of all
cholesterol in the body (Dietschy and Turley, 2001). About
70% is found in myelin (Petrov et al., 2016), and around
30% in membranes of neuronal and glial cells, where it is
metabolically active and undergoes recycling for neuron repair
and remodeling (Dietschy and Turley, 2004). It constitutes a
crucial component of cell membranes (Herz and Bock, 2002),
andmyelin sheath which provides insulation for the transmission
of nerve impulses, where its loss inevitably causes neurological
difficulties. It influences the functioning of brain synapses and is
pivotal in both production, and secretion of neurotransmitters.
A connection allying cholesterol metabolism deficiencies and
neurodegenerative processes has been acknowledged (Petrov
et al., 2016).
The initial studies on cholesterol and cognition by
Sparks et al. (1990, 1994) sparked numerous research on
cholesterol and cognitive impairment, some suggesting that
hypercholesterolemia may be an important risk factor of
neurodegenerative diseases (Liu et al., 2016). Research showed
that demented or cognitively impaired aging adults show
an increase in plasma total cholesterol (TC) or low-density
lipoprotein cholesterol (LDL), as compared to non-demented
individuals of the same gender and age (Evans et al., 2000;
Lesser et al., 2001; Yaffe et al., 2002). Several, although—in
most cases—retrospective epidemiological studies, mentioned
a smaller rate of Alzheimer’s disease (AD) amongst patients
taking statins (Jick et al., 2000; Wolozin et al., 2000, 2007;
Cramer et al., 2008; Haag et al., 2009). Stronger evidence,
causally connecting cholesterol with AD was revealed by
experimental studies indicating that controlling the amount
of this lipid, altered the concentrations of amyloid precursor
proteins (APP) and beta-amyloid (Friedhoff et al., 2001).
Nevertheless, several uncertainties regarding the supposition
causally connecting cholesterol with AD have emerged. Some
studies failed to observe the discrepancies or indicated that
cholesterol concentrations in AD patients were lower than
non-demented individuals (Romas et al., 1999; Slooter et al.,
1999; Kalmijn et al., 2000; Knittweis and McMullen, 2000; Tan
et al., 2003), reporting negative correlations of serum lipid
values with AD (or with all dementias; Solfrizzi et al., 2002;
Mielke et al., 2005). Also, prospective studies on statins and
AD have not entirely supported those associations (Rea et al.,
2005; Zandi et al., 2005; McGuinness et al., 2013). Clinical
interventions manipulating statins to lower cholesterol levels
to prevent and cure neurodegeneration proved unsuccessful
(McGuinness et al., 2014). Even experimental data is open
to different interpretations, as modifying cholesterol levels
impacts various proteins, not confined to APP and beta-amyloid
(Wood et al., 2014). Additionally, peripheral cholesterol cannot
cross the blood-brain barrier (BBB; Björkhem and Meaney,
2004). The aforementioned presumptions do not validate the
causing role of elevated cholesterol concentrations in AD or
mild cognitive impairment (MCI; Liu et al., 2016). At present,
molecular mechanisms constituting neurodegeneration remain
unclear and we have no valid blood indicators for initial
diagnosis. The inconsistency of the findings of numerous
up-to-date scientific investigations suggests that added efforts
aimed at the observation and analysis of lipid measurements
are needed, especially as blood-based biomarkers are easily
acquired, relatively inexpensive, and more feasible for extensive
application than cerebrospinal fluid (CSF) markers.
Over the years, the variable that began being associated with
neurodegenerative processes is the modified metabolism of brain
cholesterol, with research suggesting that oxidized derivatives
of cholesterol—oxysterols (OHC)—might be amongst the most
important determinants of AD. They are biologically active
cholesterol metabolites circulating in plasma that may be formed
enzymatically or by autoxidative mechanisms (Dias et al., 2018).
Oxysterols, such as 27-OHC, 24S-OHC, 7α-OHC i 7β-OHC not
only penetrate the BBB but exhibit cytotoxic and proapoptotic
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potential. Among those, 24S-OHC is the most prevalent in the
brain. It modulates cholesterol homeostasis and aids neuronal
activity through the activation of liver X receptors (Okabe et al.,
2013). The elevation of 24S-OHC in plasma in the course
of neurodegenerative disorders is believed to show neuronal
atrophy and growing secretion to the circulation; therefore, it is
possibly mostly related to neurocognitive disorder pathogenesis
(Testa et al., 2016).
24(S)-hydroxycholesterol [24(S)-OHC]
The conversion of cholesterol to 24S-OHC is catalyzed by
cholesterol 24-hydroxylase (CYP46A1), abundantly expressed
in the brain (Boussicault et al., 2016). Plasma concentration
of 24(S)-hydroxycholesterol [24(S)-OHC] depends on various
determinants, including cholesterol turnover factors, liver
oxysterol elimination, plasma lipoprotein metabolism, genetics,
and behavioral patterns (Leoni and Caccia, 2013). It has been
hypothesized that plasma levels of 24(S)-OHC can serve as
the first biochemical indicators of modified homeostasis of
cholesterol in the central nervous system (CNS; Lütjohann
et al., 2000). Further research delivered contradictory outcomes,
reporting normal (Schönknecht et al., 2002) or lowered
(Bretillon et al., 2000; Kölsch et al., 2004; Solomon et al.,
2009) levels of 24(S)-OHC in demented vs. cognitively normal
individuals. Some studies indicate that plasma concentrations
of 24(S)-OHC may be higher in initial AD and Vascular
dementia (VaD), possibly due to cholesterol turnover elevation
associated with neuronal degradation or a defect in the BBB,
present in neurodegenerative disorders, including AD (Zuliani
et al., 2011). BBB defects, the occurrence of inflammation,
or elevated cholesterol turnover can all counterbalance this
notion, causing an increase in, or—occasionally—modification
of 24(S)-OHC plasma concentrations. Similarly, reduction of
those levels in severe dementia can be associated with the
deficit of metabolically active neurons and the atrophy level
of cell membranes (Schönknecht et al., 2002). Scarce work
has focused on the evaluation of the associations between
oxysterols and MCI (Liu et al., 2016). Initial reports suggest
that increased concentrations of 24(S)-OHC (Leoni et al.,
2006) or 27(S)-hydroxycholesterol (27-OHC; Liu et al., 2016)
in CSF can pose a neurodegeneration indicator in individuals
with MCI.
MATERIALS AND METHODS
The study was conducted with retrospective use of selected
data and biological material from a nationwide cross-sectional
PolSenior project carried out between 2007 and 2012. The project
originally involved 5,695 respondents, of which 4,979 were aged
65 years and over, and 716 aged 55–59 years. Participants had
been subject to randomized selection from 16 administrative
zones of Poland by a multi-stage, proportional, age-group
stratified process, as outlined previously (Bledowski et al.,
2011). The study fully complied with all applicable institutional
and governmental regulations concerning the ethical use
of human volunteers, and with the terms of the Helsinki
Declaration. The institutional review board approved the
study protocol (the Bioethics Committee of the Medical
University of Silesia in Katowice, Poland; no KNW-6501-
38/I/08) and all the recruited subjects gave their written
informed consent.
Participants
The study sample consisted of 230 subjects, including 109 women
and 121 men, aged 65+ years selected amongst the PolSenior
project respondents from the kujawsko-pomorskie voivodeship.
The sampling followed strict exclusion criteria: (1) statin
ingestion; (2) symptoms of depression—Geriatric Depression
Scale 15-item version (GDS-15) >5 points; (3) moderate or
severe dementia; (4) brain stroke; and (5) other pathological
states that could severely influence cognitive functioning. To
ensure comparability, analyses were conducted in three age-
and gender-matched groups of cognitive performance:
cognitively normal, MCI, and mild dementia. Cognitive
function was screened using the Mini–Mental State Examination
(MMSE; Folstein et al., 1975). The total score of MMSE is
30 points, of which 30–28 points were considered as the
cognitive norm, 27–24 points as MCI, and 23–20 points as
mild dementia. The test had been administered by trained
nurses. The overall cognitive score was based on the MMSE
result alone.
Biochemical Parameters
Blood samples were obtained from each participant during a
home visit by vacuum venipuncture to ensure transport safety.
Samples were delivered by nurses within a maximum of 2 h
to project local laboratories, where after separating serum
and plasma they were stored at −20◦C until analysis. Serum
concentrations of TC (measurement range: 3–800 mg/dl;
error: <1.7%), LDL (measurement range: 3–550 mg/dl;
error: <1.2%) and high-density lipoprotein (HDL; measurement
range: 3–120 mg/dl; error: <1.3%) were assayed in the
Central Laboratory in Warsaw with the use of an enzymatic
colorimetric method (Modular PPE, Roche Diagnostics,
Mannheim, Germany). Plasma concentrations of 24(S)-OHC
(test sensitivity: 0.78 ng/ml) were assayed in the Department and
Clinic of Geriatrics Collegium Medicum in Bydgoszcz with the
use of the ELISA immunoenzyme assay.
Functional Assessment
We conducted a retrospective analysis of respondent
data, including chosen clinical parameters (age, gender,
socioeconomic data, health, and lifestyle), and results of GDS-15
(Sheikh and Yesavage, 1986), Katz Index of Activities of Daily
Living (ADL; Katz et al., 1970), and Lawton Instrumental
Activities of Daily Living Scale (IADL; Lawton and Brody, 1969),
which is reported in the sample description below.
Statistical Analyses
The main analyzed variable regarding cognitive functioning
level was the MMSE test result. It was explored regarding both
plasma 24(S)-OHC and serum lipid levels, with the use of
appropriate statistical methods, as detailed below. The functional
assessment (e.g., chosen clinical parameters, ADL, and IADL
test results) was used to describe the study sample. Statistica
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10.0 (StatSoft, Inc., 2016), R statistical packet (R Core Team,
2016) and RStudio environment (RStudio Team, 2016) were
used for all analyses. Normally distributed data (serum lipid
levels) are presented as mean ± standard deviation and were
analyzed using the independent-samples t-test or ANOVA with
the RiR Turkey test, as appropriate. Not-normally distributed
data (plasma lipid levels) are presented as median with one and
three quartiles and were analyzed using the Mann–Whitney
U test or the Kruskal–Wallis test, as appropriate. Correlations
were assessed using the Spearman Rank correlation test for





Cognitively normal, referred to as control group, consisted of
71 subjects (33 women and 38 men, with the average age
of 77.8); MCI group consisted of 85 participants (43 women
and 42 men, with the average age of 78.8); mild dementia
group consisted of 74 subjects (33 women and 41 men,
with the average age of 80.7). The study sample was age-
and gender-matched. The sample was homogenous regarding
the assessed socioeconomic, lifestyle, and health factors that
could affect cognitive performance. The vast majority (78%)
achieved the primary or vocational education level. Ninety-
seven percentage were employed at some part of their lives,
where 71% were physical laborers or farmers. Seventy-six
percentage received their financial situation as good. The sample
was very homogenous in terms of having children—95% had
them. Seventy-six percentage reported undertaking activities
requiring physical activity in the last 12 months, however,
the group was not physically active in general. Current
participation in exercise or rehabilitation was declared by only
13% of the respondents, and exercising or undertaking sports
activities in the past–14%. The ability to climb the 1st floor
was declared by 89%, while 13% thought they could swim
10 m. The majority declared good health; 18% had the legal
title of being disabled; 87%—normal thyroid function, and
the remaining—subclinical thyroid disease; 73%—no vision
problems. Ninety-five percentage did not report a history of
depression treatment. Eighty-four percentage declared their
alcohol intake to be not more than a few servings a year. Eighty-
four percentage of respondents were completely independent in
basic ADLs. The most differentiating variables were the declared
ability to ride a bike (59% non-riders and 41% riders), smoking
(43% of former/current smokers vs. 57% of non-smokers), and
independence in instrumental ADL, declared by only 53% of the
respondents (Tables 1, 2).
Plasma Concentrations of 24(S)-OHC
No statistically significant differences were found in 24(S)-OHC
concentrations for different groups of cognitive performance.
No statistically significant differences were found in 24(S)-OHC
concentrations based on gender (Tables 3, 4).
TABLE 1 | Activities of daily living (ADL) results of the study sample.




ADL interpretation: 5–6 points: no disorders. 3–4 points: moderate impairment. 0–2
points: severe impairment.
TABLE 2 | Instrumental activities of daily living scale (IADL) results of the study
sample.




IADL interpretation: 8–18 points: severe dependence. 19–23 points: moderate
dependence. 24 points: full independence.
TABLE 3 | Plasma 24(S)-OHC levels [median (1 quartile–3 quartile)] and cognitive
performance measured with the Mini-Mental State Examination (MMSE).
Cognitive functioning level K–W
Norm MCI Mild dementia p level
24(S)-OHC 199.7 209.8 200.2 0.225
[184–222.1] [193.3–224.3] [178.6–216.3]
TABLE 4 | Plasma 24(S)-OHC levels [median (1 quartile–3 quartile)] and gender.
Gender
U M–W
Women Men p level
24(S)-OHC 206.0 [182.2 – 225.1] 201.9 [184.0 – 218.4] 0.503
Serum Concentrations of TC, LDL, and
HDL
Statistically significant differences were found in serum TC
(p = 0.026) and LDL (p = 0.007) concentrations for different levels
of cognitive performance. No statistically significant differences
between serum HDL concentrations and cognitive performance
were found (Table 5). We found no statistically significant
correlations between 24(S)-OHC and TC, LDL, HDL.
TC was the highest in the MCI group (222.4 ± 47.1),
and lowest in mild dementia (205.0 ± 38.0). In the cognitive
norm, it was 208,6 ± 42,3. LDL concentration was the
highest in the MCI group (142.1 ± 38.4), and lowest
in cognitive norm (125.5 ± 37.1). In the mild dementia
group, the LDL level was 125.9 ± 32.6. Multiple regression
revealed statistically significant differences in LDL levels between
the cognitive norm and MCI (p = 0.020), and MCI and
mild dementia (p = 0.014). For TC, statistically important
differences occurred between MCI and mild dementia only
(p = 0.029; Table 6, Figures 1–3). We found no statistically
significant correlations between 24(S)-OHC and TC, LDL, HDL
(Table 6).
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TABLE 5 | Serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL),
and high-density lipoprotein cholesterol (HDL) concentrations (mean ± SD) with
cognitive performance measured with the MMSE.
Cognitive functioning level
ANOVA
Norm MCI Mild dementia p-level
TC 208.6 ± 42.3 222.4 ± 47.1 205.0 ± 38.0 0.026
LDL 126.5 ± 37.1 142.1 ± 38.4 125.9 ± 32.6 0.007
HDL 48.6 ± 12.3 48.6 ± 12.5 52.5 ± 15.1 0.109





FIGURE 1 | Serum total cholesterol (TC) concentrations and
cognitive performance.
FIGURE 2 | Serum low-density lipoprotein cholesterol (LDL) concentrations
and cognitive performance.
DISCUSSION
Cholesterol homeostasis disorders can impact dementia
progression (Liu et al., 1998; Björkhem, 2006). As mentioned
before, plasma levels of 24(S)-OHC can reflect brain cholesterol
catabolism and in consequence—ongoing neurodegeneration.
FIGURE 3 | Serum high-density lipoprotein cholesterol (HDL) concentrations
and cognitive performance.
Therefore, possibly the plasma concentrations of this parameter
could be a candidate biochemical marker of altered homeostasis
of cholesterol in CNS (Lütjohann et al., 2000). Studies on plasma
24(S)-OHC levels in the context of dementia have brought
conflicting results throughout (Bretillon et al., 2000; Lütjohann
et al., 2000; Schönknecht et al., 2002; Kölsch et al., 2004;
Solomon et al., 2009) with an interesting hypothesis of higher
concentrations of brain cholesterol when neurodegeneration
markers are elevated, but neuron loss and brain atrophy degree
remains small (Zuliani et al., 2011). This is following other
clinical observations (Kölsch et al., 2004; Solomon et al., 2009),
also indicating that lowered plasma 24(S)-OHC levels are typical
for dementia (Liu et al., 1998; Leoni and Caccia, 2013), but
they lower gradually with disease progression (Björkhem and
Meaney, 2004). According to this hypothesis, we expected
24(S)-OHC levels to be elevated in the mild dementia group in
comparison with the cognitive norm; however, this assumption
was not confirmed. Perhaps more than one measurement in
the course of the disease is required to capture its progression
reflected by plasma lipid levels. It was previously demonstrated
that plasma levels of both 24-OHC and 7-OHC, but not 27-OHC
were higher in demented vs. non-demented individuals, and
might be lowered by simvastatin (Vega et al., 2004; Vega and
Weiner, 2007).
Few studies assessed correlations between oxysterols andMCI
(Tan et al., 2003; Liu et al., 2016), providing conflicting results of
either elevated or lowered plasma 24(S)-OHC levels (Lütjohann
et al., 2000; Papassotiropoulos et al., 2000). Again, the hypothesis
of higher plasma levels of 24(S)-OHC in an early MCI, compared
to significant neuron loss stage has been raised (Hughes et al.,
2013), for contradictory results might have been caused by
research groups with varying MCI duration. Advanced disease
was associated with neuronal atrophy and decrease of 24S–OHC,
while its onset—with the elevated level of this oxysterol. Possibly
the differences resulted from cholesterol release due to the
myelin breakdown (Hughes et al., 2013). It seems plausible,
since conflicting research, e.g., study by Liu et al. (2016) that
found no significant differences in plasma concentrations of
24(S)-OHC between individuals with and without MCI, did
not allow to observe the impairment progression. Similarly,
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our case-control study showed no significant differences in
24(S)-OHC concentrations amongst cognitively normal, MCI
and mild dementia patients, thus failing to demonstrate an
indicative role of this oxysterol for MCI. There are, therefore,
certain premises that lowering plasma levels of 24(S)-OHC can
be related to cognitive impairment progression, characterized
by loss of metabolically active neurons. According to this
hypothesis, elevated cholesterol turnover would counteract this
tendency (Schönknecht et al., 2002). However, to test it,
prospective studies with multiple measurements of this oxysterol
are needed.
Blood lipids can directly affect neurodegeneration (Bretillon
et al., 2000; Schönknecht et al., 2002; Kölsch et al., 2004; Li
et al., 2005; Fischer et al., 2006; Hall et al., 2006; Reitz et al.,
2008; Solomon et al., 2009). Serum TC levels were significantly
higher inMCI than in mild dementia, and serum LDL levels were
significantly higher in MCI than in cognitively normal and mild
dementia groups. HDL levels did not vary significantly between
the study populations. Our findings of concentrations of both TC
and LDL fraction highest in the MCI group might indicate that
this diagnostic entity should be further explored in concerning
blood lipid levels. Because those can be altered by eating
habits, physical activity, pharmaceuticals, and modification of
harmful behaviors, such as tobacco use, the above results might
carry major public health implications. Approaches aiming at
modification of blood lipid levels may therefore pose feasible
large-scale interventions intended for preserving brain function
over the years.
So far, findings from investigations on serum lipid levels
and cognitive performance have lacked consistency (Kivipelto
et al., 2001; Michikawa, 2003; Li et al., 2004; Mielke et al.,
2005), similarly to the results of studies on relationships
between advanced age lipids with cognitive decline or dementia.
We found TC levels significantly different between the study
populations; they were lowest in mild dementia, which supports
earlier reports on lower TC levels in demented patients (Kuusisto
et al., 1997; Panza et al., 2006), as compared to non-demented
individuals, even upon completion of a 26-year follow-up
(Stewart et al., 2007). The prevailing view, however, has been
that elevated cholesterol constitutes a risk factor for dementia.
Substantial data have confirmed that both high risk of AD
development (Patterson et al., 2008), and considerably increased
likelihood of MCI (Piguet et al., 2003), are associated with high
TC (Patterson et al., 2008) regardless of possible interfering
factors, being indicative of playing a role in developing cognitive
impairment (Piguet et al., 2003). In our sample, the highest TC
levels were indeed found in the MCI group, which seems to
favor this notion. Nonetheless, the process by which high TC
could contribute to cognitive decline remains uncertain. Previous
data suggested both that modifications of brain cholesterol
homeostasis might be associated with the core pathological
characteristics of AD, specifically beta-amyloid (Burns and Duff,
2002; Sponne et al., 2004), and that elevated TC in advanced
age does not correlate with any form of cognitive decline or
dementia (Kivipelto et al., 2001; Beydoun et al., 2011; Anstey
et al., 2017). On the contrary, it seems to be linked to a
reduced probability of incident AD in older adults (Kuusisto
et al., 1997), acting as a preventive measure against cognitive
impairment (Piguet et al., 2003). Rather, mid-age elevated levels
of TC are connected with an increased odds ratio for MCI
and cognitive deterioration in old age (Anstey et al., 2017).
The explanation of those discrepancies might partly lie in the
moment of cholesterol level assessment regarding the clinical
onset of dementia, indicating that TC starts decreasing years
before the manifestation of the symptoms, possibly due to
ongoing neurodegeneration. This study, providing a one–time
measurement of blood lipids in advanced-age individuals, and
thus not allowing to observe cholesterol dynamics in the sample
over years, warns against drawing bold conclusions regarding
the potential of research on TC regarding cognitive decline.
However, our findings of lowest TC in mild dementia, medium
in the cognitive norm and highest in MCI seem to partly support
the above interpretation.
Regarding cholesterol fractions, an Indian study, assessing
lipid profiles in similar groups of cognitive functioning, reported
AD patients with higher levels of LDL, and lower HDL
(Vasantharekha et al., 2017). Additionally, a longitudinal study
on 1,159 elderly Chinese revealed correlations of both high TC
and LDL concentrations with rapid cognitive deterioration (Ma
et al., 2017). It is partially consistent with our findings of the
highest levels of both TC and LDL in the MCI group, and
lowest LDL in the cognitive norm, which was expected. As to
HDL levels, they did not differ significantly between the groups.
We find it surprising, a majority of transverse investigations
which involved individuals aged 75 plus, did recognize a link
between high HDL levels and improved results of cognitive
ability examinations (van Vliet et al., 2009). Some recent studies,
however, failed to demonstrate both advanced age HDL and
triglyceride correlation with a high probability of developing
VaD, and HDL with MCI, AD, or other dementia disorders,
respectively (Anstey et al., 2017). It ought to be noted that
conflicting findings might be derivatives of differences in study
and population type selected, age of participants, sampling,
diagnostic procedures, methods and measures used, scientific
rigor applied, making the results inappropriate for direct
comparisons. Consequently, even though research on cholesterol
and cognition was initiated decades ago, the associations between
blood lipids and cognition are not yet fully understood (Li et al.,
2018). We believe that this study with its stringent exclusion
criteria, allowed to eliminate the plethora of confounding factors
regarding cognitive functioning, thus constituting a valuable
reference for further debate.
The study sample was homogenous concerning the majority
of the analyzed socioeconomic, lifestyle, and health factors which
could impact cognitive functioning (except for smoking and
riding a bike). Therefore, it seems justified to test a hypothesis
of cognitive functioning level differences resulting from other
uncontrolled variables, such as diet or psychological factors.
Limitations to this study, mainly resulting from the nature
and design of the PolSenior project, have to be taken into
consideration; as a cross-sectional, multicenter, community-
based project involving nearly 6,000 participants, only routine
screening examination of cognition, mood, and functional
dependence was performed. Although providing a multi-aspect
Frontiers in Aging Neuroscience | www.frontiersin.org 6 November 2020 | Volume 12 | Article 590546
McFarlane et al. Blood Lipids and Cognitive Performance
assessment to a sample this size, representative for the elderly
population of a country, definitely constitutes a significant
scientific achievement, it also contributes to certain problems,
including those of a methodological nature. No results of further
detailed assessments are available, including brain imaging
data. Findings of this case-control study on aging Polish
adults need to be confirmed in further longitudinal studies,
and cannot be generalized to other populations. Even though
discrepancies amongst study populations have been noted for
various lipid parameters, the numerical differences are small.
Perhaps population type, diagnostic procedure, or statistical
significance could influence data precision. To seize the overall
impact of blood lipids on cognitive capabilities more accurately,
longitudinal studies spanning over middle-aged individuals and
seniors, on several constant lipoproteins and cognitive measures,
are necessary. Also, usage of MMSE, not entirely adjusted to
the Polish population of the older adults, lacking norms for
under-educated individuals, can potentially lead to research
bias of underestimating the cognitive performance in a part
of the sample. Under-educated individuals might have scored
lower as a result of their lack of general knowledge and overall
poor level of cognitive performance, which, for them is normal
functioning, not indicative of cognitive impairment. This may
apply to 26 respondents, constituting 12% of the study sample,
who achieved only incomplete primary education, including
two people with no education, being probably self-educated in
terms of reading, writing, and counting. An interesting for the
analyses is the fact that, to our best knowledge, there are no
MMSE norms for the Polish population, defined by the sum of
points on the scale, constituting cut-off points for subsequent
levels of cognitive impairment severity. Determining the ceiling
for the under-educated—mostly due to the historical factors—the
older population of Poland requires further discussion and
research. Application of a full battery of neuropsychological
tests would enable a comprehensive cognitive assessment and
improve its accuracy, however, the nature and range of the
project impeded it. Therefore, although the understanding of
blood lipid profiles in the study population is not thorough,
they may serve as a base for further exploration, setting
out the framework and reference for future research. Despite
limitations, it is one of few studies thoroughly investigating blood
lipid roles of both circulating and brain lipids concerning the
cognitive functioning of the elderly in Poland, also addressing
potential blood biomarkers of an early cognitive decline among
aging adults.
CONCLUSION
Following the criteria for potential blood biomarkers of early
neurodegeneration, we can assume that 24(S)-OHC cannot
aspire to a biomarker of an early cognitive decline in the
elderly. To fully assess the potential of research on cholesterol
in the context of a cognitive decline, longitudinal cross-sectional
studies aimed at further exploring blood lipid profiles in
both the initial and advanced MCI and dementia, are needed.
Upcoming studies dedicated to determining the processes that
constitute the foundation of the influence of plasma lipids on
cognition are hoped to deliver a pivotal view on the triggers
and interrelationships of MCI and dementia, as well as prompt
original approaches for managing these conditions.
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